

## Summary of Available Influenza Products— 2015-2016 Influenza Season<sup>1,\*</sup>

Vaccine	Age Indications	Contraindications <sup>a</sup>	Precautions <sup>a</sup>
<b>Quadrivalent</b>			
Live attenuated influenza vaccine (LAIV4; administered IN)	Healthy nonpregnant persons aged 2 through 49 years	<p>Severe allergic reaction to any vaccine component, including egg protein, or after previous dose of any influenza vaccine.</p> <p>Concomitant use of aspirin or aspirin-containing medications in children and adolescents.</p> <p>In addition, ACIP recommends LAIV4 not be used for pregnant women, immunosuppressed persons, persons with egg allergy, and children aged 2 to 4 years who have asthma or who have had a wheezing episode noted in their medical record within the past 12 months, or for whom parents report that a health care provider stated that they had wheezing or asthma within the last 12 months.</p> <p>LAIV should not be administered to persons who have taken influenza antiviral medications within the previous 48 hours. Persons who care for severely immunosuppressed persons who require a protective environment should not receive LAIV, or should avoid contact with such persons for 7 days after receipt.</p>	<p>Moderate to severe acute illness with or without fever.</p> <p>History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine.</p> <p>Asthma in persons aged 5 years and older.</p> <p>Medical conditions which might predispose to higher risk for complications attributable to influenza.</p>
Inactivated influenza vaccine (IIV4; administered IM or ID)	Persons aged ≥6 months <sup>b</sup>	Severe allergic reaction to any vaccine component, including egg protein, or after previous dose of any influenza vaccine.	Moderate to severe acute illness with or without fever; history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine.

Abbreviations: IM = intramuscular; ID = intradermal; IN = intranasal

<sup>a</sup>Immunization providers should check Food and Drug Administration–approved prescribing information for 2015–16 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for US-licensed vaccines are available at <http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.htm>.

<sup>b</sup>Not all brands are indicated for this age range.

<b>Trivalent</b>			
Inactivated influenza vaccine (IIV3; administered IM)	Persons aged $\geq 6$ months <sup>b</sup>	Severe allergic reaction to any vaccine component, including egg protein, or after previous dose of any influenza vaccine.	Moderate to severe acute illness with or without fever; history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine.
Cell culture-based inactivated influenza vaccine (ccIIV3; administered IM)	Persons aged $\geq 18$ years	Severe allergic reaction to any vaccine component, including egg protein, or after previous dose of any influenza vaccine.	Moderate to severe acute illness with or without fever; history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine.
Recombinant influenza vaccine (RIV3; administered IM)	Persons aged $\geq 18$ years	Severe allergic reaction to any vaccine component.	Moderate to severe acute illness with or without fever; history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine.

<sup>b</sup>Not all brands are indicated for this age range.

\* We have included information from the 2015-2016 influenza season here for your reference only. For the most recent ACIP influenza guidelines or recommendations, always check the Centers for Disease Control and Prevention website or [Whatsyourfluplan.com](http://www.cdc.gov/flu/fluplan).

**REFERENCE: 1.** Grohskopf L, Sokolow LZ, Olsen SJ, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2015-16 influenza season. *MMWR Morb Mortal Wkly Rep.* 2015;64(30):818-825. <http://www.cdc.gov/mmwr/pdf/wk/mm6430.pdf>.